Stock Traders Purchase Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the target of some unusual options trading on Wednesday. Investors bought 1,002 put options on the stock. This is an increase of approximately 1,791% compared to the average volume of 53 put options.

Institutional Investors Weigh In On Maravai LifeSciences

Institutional investors and hedge funds have recently made changes to their positions in the company. 12 West Capital Management LP boosted its position in shares of Maravai LifeSciences by 8.0% in the 1st quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company's stock worth $27,672,000 after purchasing an additional 930,000 shares during the last quarter. Alyeska Investment Group L.P. increased its holdings in Maravai LifeSciences by 145.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company's stock valued at $29,045,000 after purchasing an additional 3,161,072 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Maravai LifeSciences by 29.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company's stock valued at $25,420,000 after purchasing an additional 1,062,485 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Maravai LifeSciences by 4.9% in the fourth quarter. JPMorgan Chase & Co. now owns 4,250,656 shares of the company's stock valued at $23,166,000 after purchasing an additional 200,411 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Maravai LifeSciences by 1.8% in the fourth quarter. Ameriprise Financial Inc. now owns 3,611,625 shares of the company's stock valued at $19,683,000 after purchasing an additional 62,123 shares during the last quarter. Institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Trading Up 10.6%

Shares of MRVI stock traded up $0.23 on Tuesday, reaching $2.40. 2,034,862 shares of the stock were exchanged, compared to its average volume of 2,347,051. The stock has a market cap of $611.18 million, a PE ratio of -1.46 and a beta of 0.19. Maravai LifeSciences has a one year low of $1.67 and a one year high of $11.50. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The stock has a 50 day moving average price of $2.09 and a 200 day moving average price of $3.96.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The business's quarterly revenue was down 26.9% compared to the same quarter last year. Equities research analysts forecast that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Craig Hallum decreased their price target on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Robert W. Baird decreased their price target on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Baird R W lowered Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Morgan Stanley cut their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Tuesday, March 25th. Finally, UBS Group cut their price objective on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $6.64.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.